Arctigenin Ameliorates Inflammation by Regulating Accumulation and Functional Activity of MDSCs in Endotoxin Shock

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Endotoxin shock is a severe condition driven by immune dysregulation.
• Myeloid-derived suppressor cells (MDSCs) play a protective role in endotoxin shock.
• Mechanisms regulating MDSCs by small molecules are not fully understood.

Purpose of the Study:

• To investigate the effect of arctigenin on MDSC accumulation and function.
• To elucidate the molecular mechanisms underlying arctigenin-mediated MDSC regulation.
• To assess arctigenin's therapeutic potential in endotoxin shock.

Main Methods:

• In vivo and in vitro experiments using LPS-induced inflammation models.
• Analysis of MDSC accumulation and immunosuppressive function.
• Molecular studies involving miR-127-5p, IRF8, Arg-1, and iNOS expression.

Main Results:

• Arctigenin induced accumulation of functional MDSCs, particularly granulocytic MDSCs (G-MDSCs).
• Arctigenin ameliorated LPS-induced inflammation by enhancing MDSC immunosuppressive activity.
• Arctigenin upregulated miR-127-5p, targeting IRF8, and increased Arg-1 and iNOS expression in MDSCs.

Conclusions:

• Arctigenin promotes MDSC accumulation and function through the miR-127-5p/IRF8 pathway.
• Arctigenin enhances MDSC immunosuppressive activity, impacting M1 macrophage polarization.
• Arctigenin shows promise as a therapeutic agent for inflammatory diseases like endotoxin shock.